Influence of FCGR3A genotype on the therapeutic response to rituximab in rheumatoid arthritis: an observational cohort study

Objectives To determine whether a polymorphism in the Fcγ receptor type IIIA (FCGR3A-F158V), influencing immunoglobulin G binding affinity, relates to the therapeutic efficacy of rituximab in rheumatoid arthritis (RA) patients. Design Observational cohort study. Setting Three university hospital rheumatology units in Sweden. Participants Patients with established RA (n=177; 145 females and 32 males) who started rituximab (Mabthera) as part of routine care. Primary outcome measures Response to rituximab therapy in relation to FCGR3A genotype, including stratification for sex. Results The frequency of responders differed significantly across FCGR3A genotypes (p=0.017 in a 3×2 contingency table). Heterozygous patients showed the highest response rate at 83%, as compared with patients carrying 158FF (68%) or 158VV (56%) (p=0.028 and 0.016, respectively). Among 158VV patients, response rates differed between male and female patients (p=0.036), but not among 158FF or 158VF patients (p=0.72 and 0.46, respectively). Conclusions Therapeutic efficacy of rituximab in RA patients is influenced by FCGR3A genotype, with the highest response rates found among heterozygous patients. This may suggest that different rituximab mechanisms of action in RA are optimally balanced in FCGR3A-158VF patients. Similar to the previously described associations with RA susceptibility and disease course, the impact of 158VV on rituximab response may be influenced by sex.

[1]  M. Dougados,et al.  Fcγ receptor type IIIA polymorphism influences treatment outcomes in patients with rheumatoid arthritis treated with rituximab , 2012, Annals of the rheumatic diseases.

[2]  Tim F. Rayner,et al.  Copy number, linkage disequilibrium and disease association in the FCGR locus , 2010, Human molecular genetics.

[3]  J. Barrett,et al.  Dissection of the FCGR3A association with RA: increased association in men and with autoantibody positive disease , 2009, Annals of the rheumatic diseases.

[4]  F. Kurreeman,et al.  Contribution of Fcγ receptor IIIA gene 158V/F polymorphism and copy number variation to the risk of ACPA-positive rheumatoid arthritis , 2008, Annals of the rheumatic diseases.

[5]  Y. Lee,et al.  Associations Between FCGR3A Polymorphisms and Susceptibility to Rheumatoid Arthritis: A Metaanalysis , 2008, The Journal of Rheumatology.

[6]  K. Kalunian,et al.  Elevated autoantibody content in rheumatoid arthritis synovia with lymphoid aggregates and the effect of rituximab , 2008, Arthritis research & therapy.

[7]  P. Kramer,et al.  17β-Estradiol utilizes the estrogen receptor to regulate CD16 expression in monocytes , 2007, Molecular and Cellular Endocrinology.

[8]  M. Lindorfer,et al.  Drug Insight: the mechanism of action of rituximab in autoimmune disease—the immune complex decoy hypothesis , 2007, Nature Clinical Practice Rheumatology.

[9]  Thomas Skogh,et al.  Fcγ receptor type IIIA genotype and response to tumor necrosis factor α-blocking agents in patients with rheumatoid arthritis , 2007 .

[10]  P. Söderkvist,et al.  The 158V polymorphism of Fc gamma receptor type IIIA in early rheumatoid arthritis: increased susceptibility and severity in male patients (the Swedish TIRA project). , 2005, Rheumatology.

[11]  E. Kimby,et al.  Polymorphisms in FcγRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenstrom's macroglobulinemia. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  P. Colombat,et al.  Rituximab-Dependent Cytotoxicity by Natural Killer Cells , 2004, Cancer Research.

[13]  K. Haas,et al.  The Innate Mononuclear Phagocyte Network Depletes B Lymphocytes through Fc Receptor–dependent Mechanisms during Anti-CD20 Antibody Immunotherapy , 2004, The Journal of experimental medicine.

[14]  M. Leandro,et al.  Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. , 2003, Arthritis and rheumatism.

[15]  I. Sanz,et al.  The relationship of FcγRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus , 2003 .

[16]  G. Salles,et al.  Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. , 2002, Blood.

[17]  R. Kimberly,et al.  A novel polymorphism of FcgammaRIIIa (CD16) alters receptor function and predisposes to autoimmune disease. , 1997, The Journal of clinical investigation.

[18]  L. Padyukov,et al.  Fcgamma receptor type IIIA genotype and response to tumor necrosis factor alpha-blocking agents in patients with rheumatoid arthritis. , 2007, Arthritis and rheumatism.

[19]  E. Kimby,et al.  Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenström's macroglobulinemia. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  I. Sanz,et al.  The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. , 2003, Arthritis and rheumatism.

[21]  M. Prevoo,et al.  Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. , 1996, Arthritis and rheumatism.